SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $35.5 million in its third quarter.
The San Francisco-based company said it had a loss of $1.87 per share. Losses, adjusted for non-recurring costs, came to $1.85 per share.
The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $2.85 per share.
The biopharmaceutical company posted revenue of $11.8 million in the period, which also beat Street forecasts. Seven analysts surveyed by Zacks expected $10.6 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NKTR at https://www.zacks.com/ap/NKTR
Copyright © 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
